Ictal and Interictal Inflammatory Markers in Migraine

Phase 4

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Treximet

Registration Number: NCT01138150

Lead Sponsor: Johns Hopkins University

Brief Summary: The purpose of this study is to evaluate blood levels of several proteins that may be altered in the inflammation associated with migraine headaches. These blood levels will be evaluated in individuals during an acute migraine attack and compared to their levels when pain free. The investigators study hypothesis is that the pro inflammatory proteins in the blood will be greater than the levels of these proteins when evaluated during a pain free period.

Detailed Description: Migraine is a common, chronic disorder, which presents with recurrent episodes of disabling headache and affects approximately 12% of American adults.1,2 No biomarkers exist to identify episodic or chronic migraine sufferers; and the diagnosis relies solely on clinical criteria. Further the full pathophysiology of migraine has not been fully delineated, although our understanding of migraine pathophysiology has dramatically improved over the past 15 years. Current theories suggest that migraine is a neurovascular disorder, with the pain of migraine a result of the release of inflammatory neuropeptides from nerve endings in the activated trigeminal system (neurogenic inflammation), ultimately resulting in vasodilation, plasma extravasation and mast cell degranulation.3-6 Several inflammatory markers have been implicated in the pathway resulting in the neurogenic inflammation of migraine including calcitonin gene related peptide (CGRP), substance P (SP), neurokinin A, and multiple cytokines such as interleukin (IL) -1, IL-6 and tumor necrosis-α (TNF-α).5,7-10 More recent research supports that the odds of migraine are increased in those who are obese and that several adipose tissue derived cytokines (adipocytokines) may contribute to the neurogenic inflammation of migraine, including leptin and adiponectin. In one small pilot study of 33 participants evaluating chronic and episodic migraineurs as compared to controls, adiponectin (an adipocytokine) was significantly elevated in chronic migraineurs as compared to controls. A second study reported low levels of another adipocytokine, leptin in episodic migraineurs. However, all of these studies have evaluated only 3 to 4 of cytokines at the same time point and 11 none have evaluated adipocytokines during an acute attack. We hypothesize that obesity-related cytokines contribute to the neurogenic inflammation of migraine and have the potential be useful as biomarkers for episodic and chronic migraine as well as new drug targets for the treatment of migraine. To this end we propose to evaluate serum levels of obesity-related cytokines in migraineurs, ictally (during an acute migraine attack), following treatment with sumatriptan/naproxen sodium (Treximet®) and interictally (at baseline) when pain free.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 36

Inclusion Criteria

Age greater than 18 years of age, migraine

Exclusion Criteria

Pregnant or breast-feeding women, presence of cardiovascular or cerebrovascular disorders as well as any known inflammatory, infectious, metabolic, thyroid, renal, cardiovascular or gastrointestinal diseases

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sugar Pill	Placebo	Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune \& inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo. Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician.
Treximet	Treximet	Fourteen participants randomized to receive Treximet (sumatriptan \& naproxen) during an acute migraine attack. Blood drawn for immune \& inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet). Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician.

Primary Outcome Measures

Name	Time	Method
Change in the Total Serum Adiponectin (T-ADP)	30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment	Change in total serum adiponectin after treatment in responders and non responders

Secondary Outcome Measures

Name	Time	Method
Middle Molecular Weight (MMW)-ADP	30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment	serum MMW-ADP levels after treatment in responders and non responders
Low Molecular Weight (LMW)-ADP	30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment	serum LMW-ADP levels after treatment in responders and non responders
Low Molecular Weight (LMW):Total (T)-ADP	30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment	serum LMW:T-ADP levels after treatment in responders and non responders
High Molecular Weight (HMW)-Adiponectin (ADP)	30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment	serum HMW-ADP levels after treatment in responders and non responders
High Molecular Weight (HMW): T-ADP	30 minutes, 60 minutes, 120 minutes after treatment	serum HMW:T-ADP levels after treatment in responders and non responders
Resistin	30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment	serum resistin levels after treatment in responders and non responders
Leptin	30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment	serum leptin levels after treatment in responders and non responders